Lu AG06466
Lu AG06466 is a pharmaceutical drug with 9 clinical trials. Historical success rate of 55.6%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
55.6%
5 of 9 finished
44.4%
4 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)
A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
Binding and Effects of Lu AG06466 in the Brain of Healthy Men
Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants
Clinical Trials (9)
Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)
A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
Binding and Effects of Lu AG06466 in the Brain of Healthy Men
Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants
A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia
Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men
Binding of Lu AG06466 in the Brain in Healthy Men
Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9